CJC-1295 DAC 5mg

CJC-1295 DAC is a synthetic analogue of growth-hormone-releasing hormone (GHRH) modified with a Drug-Affinity-Complex (DAC). The DAC moiety binds circulating serum albumin, which substantially extends the molecule's half-life relative to the No-DAC form known as modified GRF 1-29. With a molecular weight of approximately 3647.19 (CAS 863288-34-0), Sova supplies CJC-1295 DAC UK as a 5mg lyophilised vial for laboratory work.

Mechanistically, the peptide is designed to engage the GHRH receptor, the same target as native GHRH. Its distinguishing feature is duration: by tethering to albumin, the DAC construct maintains receptor-relevant exposure over a far longer window than short-acting GHRH fragments. This property makes it a useful tool for studying sustained versus pulsatile receptor activation in growth-hormone-secretagogue research at the cellular and preclinical level.

In the published literature, CJC-1295 DAC is studied within growth-hormone-secretagogue research, where investigators compare DAC and No-DAC analogues to characterise GHRH-receptor signalling kinetics. Sova provides the peptide solely as a characterised reference compound, allowing laboratories to model extended receptor engagement in vitro or in preclinical systems. No physiological or performance outcome is claimed or implied by its supply.

Each batch is analysed by HPLC alongside mass spectrometry to confirm sequence identity and purity, with a batch-linked Certificate of Analysis provided for every vial. Store the sealed, lyophilised peptide frozen and away from light, and reconstitute only under controlled laboratory conditions. Sova is a UK-based supplier offering this material for laboratory research use only, and it is not for human or animal use.